Selvita Expands its Proteomics Services Offer
Selvita has expanded its portfolio of protein chemistry services.
Analysis, production and purification of recombinant proteins remain the major activities of Selvita’s Protein Chemistry Laboratory. These projects require high expertise in the design of genetic constructs, determination and selection of the optimal expression conditions and finally production and purification of recombinant proteins with highest purity and biological activity.
“Being aware of the importance of the protein targets at every step of the preclinical drug discovery process, we place a great emphasis on the quality of our protein products. The highest purity and biological activity of the proteins, which we deliver to our customers, are our major objective and concern,” said Dr Justyna Stec-Niemczyk, Head of the Protein Chemistry Laboratory.
Due to the dynamic development of the Protein Chemistry Laboratory and constantly increasing portfolio of customers, Selvita is currently increasing its capabilities in terms of proteomic analyses. These analyses can be used for instance for biosimilar product characterization, which are currently of high interest to many biotechnology companies. Expansion of the service offer is possible due to the access to the extended range of the state of the art scientific equipment. This includes highly sophisticated mass spectrometers (e.g., MALDI-TOF MS microflex LT, LC/MS ESI/Apci Q-TOF plus, LC/MS/TSQ, LC/RAPID/MS/DAD/ESI/IT), additional ultra HPLC systems with the range of the specialized detectors (e.g. UV-VIS, RI, DAD, ELSD, Corona CAD, MALS, DLS, FLD); and microscale thermophoresis measurement devices (Nanotemper Monolith NT).
Selvita’s protein chemistry offer, in addition to already available services such as, protein assays and PAGE patterns, LC services, N-terminal protein sequencing and amino acid analyses, CD spectra analyses and the crystallographic studies, now also includes
• Determination of intact mass of proteins including large proteins,
• Analysis of the posttranslational modifications,
• Determination of protein oligomeric state (quaternary structure) and aggregation
• Protein conformation stability
• Biophysical methods for the determination of various parameters of protein-protein and protein-ligand interactions.
Related News
-
News Understanding the Benefits and Advances of Cleanroom Technology
In an industry where precision and sterility are crucial concerns, cleanrooms play a vital role in maintaining the integrity of pharmaceutical products like drugs, vaccines, and other medical products. So, what is a cleanroom?
-
News AbbVie secures GBP£1.2 billion deal for Gilgamesh’s psychedelic programme
AbbVie has penned a significant agreement to acquire the bretisilocin programme from Gilgamesh Pharmaceuticals for up to £1.2 billion, marking a bold step in the pharmaceutical giant's quest to develop treatments for psychiatric disorders. -
News Gates Foundation commits US$2.5 billion to women’s health research
The Bill & Melinda Gates Foundation has announced a substantial US$2.5 billion commitment to accelerate research and development focused exclusively on women's health through 2030.
-
News Mid-year review: notable FDA drug approvals of 2025
As we fly past the halfway point of 2025, the pharmaceutical landscape reliably continues to evolve with innovative therapies addressing critical medical needs. The FDA has already approved 17 groundbreaking medications this year, each representin... -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience.